Rosemary Andrianakos
Family Medicine · Denver, CONPI 1427464171
Payments from drug & device makers
Across 131 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$913
- AstraZeneca$348
- Lilly USA, LLC$237
- GSK$204
- Amgen$111
- Grifols USA, LLC$110
- plus $611 from 21 others
What the payments were for
- Food & beverage$2,50099%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $913 |
| AstraZeneca | 20 | $348 |
| Lilly USA, LLC | 14 | $237 |
| GSK | 10 | $204 |
| Amgen | 6 | $111 |
| Grifols USA, LLC | 5 | $110 |
| Corium, LLC | 3 | $54 |
| Novo Nordisk | 3 | $50 |
| Johnson & Johnson | 3 | $47 |
| Bristol Myers Squibb | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Boehringer Ingelheim | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $28 |
| Merck | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$2,535 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 74 | $54,488 |
| VraylarCariprazine Hcl | 18 | $26,407 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $18,779 |
| EliquisApixaban | 22 | $17,313 |
| MounjaroTirzepatide | 14 | $14,051 |
| OzempicSemaglutide | 14 | $13,927 |
| Repatha SureclickEvolocumab | 13 | $13,902 |
| LyricaPregabalin | 12 | $11,231 |
| MyrbetriqMirabegron | 19 | $9,181 |
| BelsomraSuvorexant | 19 | $8,064 |
| DayvigoLemborexant | 19 | $6,553 |
| DuleraMometasone/Formoterol | 12 | $4,247 |
| Lidocaine | 37 | $3,471 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $3,457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $348 | $54,48874 claims |
| PfizerEliquis, Lyrica | $20 | $28,54434 claims |
| AbbVieVraylar | $913 | $26,40718 claims |
| GSKTrelegy Ellipta | $204 | $18,77920 claims |
| Lilly USA, LLCMounjaro | $237 | $14,05114 claims |
| Novo NordiskOzempic | $50 | $13,92714 claims |
| MerckBelsomra, Dulera | $28 | $12,31131 claims |
| Eisai Inc.Dayvigo | $14 | $6,55319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Denver
- Mia ScottDenver$993K
- Ethan LazarusDenver$688K
- Judith ShlayDenver$264K
- Mark DeutchmanDenver$258K
- Johnny ShenDenver$182K
- Flory KreutterDenver$118K
- Nathaniel MooreDenver$21K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.